Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
16 results
  • Multiple Myeloma

15-522          Phase I

A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma (View details on clinicaltrial.gov)

  • Multiple Myeloma

19-893          Phase I

A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF CC-93269, A BCMA X CD3 T CELL ENGAGING ANTIBODY, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (View details on clinicaltrial.gov)

  • Cellular Therapy, Multiple Myeloma

19-877          Phase I

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4) (View details on clinicaltrial.gov)

  • Multiple Myeloma

16-237          Phase I

A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (anti-PDL1) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma (View details on clinicaltrial.gov)

  • Multiple Myeloma

20-081          Phase I

A Phase 1b Trial of Mavorixafor, an Oral CXCR4 Antagonist, in Combination with Ibrutinib in Patients with Waldenstrom’s Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 (View details on clinicaltrial.gov)

  • Multiple Myeloma

20-409          Phase II

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma (View details on clinicaltrial.gov)

  • Multiple Myeloma

19-054          Phase II

A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety And Tolerability, Pharmacokinetics And Preliminary Efficacy of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (View details on clinicaltrial.gov)

  • Cellular Therapy, Multiple Myeloma

18-604          Phase II

A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2). (View details on clinicaltrial.gov)

  • Cellular Therapy, Multiple Myeloma

20-518          Phase I

A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (View details on clinicaltrial.gov)

Showing 1 - 10 of 16 results